tiprankstipranks
Trending News
More News >
AlzChem Group AG (DE:ACT)
XETRA:ACT
Advertisement

AlzChem Group AG (ACT) AI Stock Analysis

Compare
27 Followers

Top Page

DE:ACT

AlzChem Group AG

(XETRA:ACT)

Rating:72Outperform
Price Target:
€182.00
▲(16.22%Upside)
AlzChem Group AG's strong financial performance is the primary driver of its score, supported by solid revenue growth and cash generation. Technical analysis reveals a bullish trend, though overbought signals may indicate a short-term price correction. The valuation suggests the stock is relatively expensive, which slightly offsets the positive financial outlook.

AlzChem Group AG (ACT) vs. iShares MSCI Germany ETF (EWG)

AlzChem Group AG Business Overview & Revenue Model

Company DescriptionAlzChem Group AG is a Germany-based specialty chemicals company operating primarily in the sectors of agriculture, fine chemicals, and metallurgy. The company specializes in the production and distribution of a wide range of chemical products, including nitriles, cyanamides, dicyandiamide, and other specialty chemicals that are essential in various industrial applications. AlzChem's products serve multiple industries such as pharmaceuticals, agriculture, automotive, and electronics.
How the Company Makes MoneyAlzChem Group AG generates revenue through the sale of its specialty chemical products across various industrial sectors. Key revenue streams include sales of agricultural chemicals that enhance crop yields and protect against pests, fine chemicals for pharmaceuticals and other high-value applications, and metallurgical products used in the production of alloys and other metal-based applications. The company benefits from strategic partnerships and long-term contracts with major industrial players, ensuring a stable demand for its products. Additionally, AlzChem invests in research and development to innovate and expand its product offerings, thereby maintaining its competitive edge in the market.

AlzChem Group AG Financial Statement Overview

Summary
AlzChem Group AG exhibits strong financial health with robust revenue growth and improved profitability. The balance sheet reflects a stable financial position, and cash flow metrics indicate effective cash generation.
Income Statement
88
Very Positive
AlzChem Group AG has demonstrated strong revenue growth, with a significant increase from 2023 to 2024. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, showcasing enhanced profitability. Both EBIT and EBITDA margins are strong, reflecting effective operational performance.
Balance Sheet
75
Positive
The company's balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. Return on equity has improved, demonstrating efficient use of equity capital. The equity ratio is stable, supporting asset financing through equity.
Cash Flow
82
Very Positive
AlzChem Group AG has shown robust growth in free cash flow, signifying improved operational efficiency. The operating cash flow to net income ratio is strong, indicating effective cash generation from operations. Free cash flow to net income ratio highlights the company's ability to convert earnings into cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue547.05M554.23M540.65M542.22M422.29M379.26M
Gross Profit340.50M339.26M304.07M282.72M268.34M250.58M
EBITDA103.04M98.44M81.75M68.06M61.89M51.39M
Net Income56.47M54.08M34.62M30.05M27.59M19.69M
Balance Sheet
Total Assets556.60M483.83M424.68M422.86M377.67M354.30M
Cash, Cash Equivalents and Short-Term Investments91.37M63.15M13.92M9.62M8.73M17.47M
Total Debt0.0052.82M62.49M100.23M55.64M69.06M
Total Liabilities333.70M276.36M261.12M276.91M288.10M285.64M
Stockholders Equity220.97M205.54M161.63M144.01M87.63M66.89M
Cash Flow
Free Cash Flow72.57M62.05M52.11M-33.31M14.48M19.88M
Operating Cash Flow121.21M105.15M72.67M-4.24M43.02M48.71M
Investing Cash Flow-37.20M-30.99M-20.55M-28.51M-28.48M-28.83M
Financing Cash Flow-28.70M-24.66M-49.17M33.65M-23.62M-11.73M

AlzChem Group AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price156.60
Price Trends
50DMA
136.28
Positive
100DMA
118.64
Positive
200DMA
89.33
Positive
Market Momentum
MACD
7.43
Negative
RSI
61.36
Neutral
STOCH
75.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ACT, the sentiment is Positive. The current price of 156.6 is above the 20-day moving average (MA) of 148.59, above the 50-day MA of 136.28, and above the 200-day MA of 89.33, indicating a bullish trend. The MACD of 7.43 indicates Negative momentum. The RSI at 61.36 is Neutral, neither overbought nor oversold. The STOCH value of 75.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:ACT.

AlzChem Group AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (44)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
€1.59B30.9329.46%1.15%2.51%56.13%
68
Neutral
€3.49B14.505.37%3.56%-10.63%-23.15%
67
Neutral
€8.36B28.073.25%6.52%0.53%
66
Neutral
€8.19B15.5511.49%3.70%0.10%-15.09%
62
Neutral
$2.25B-3.92%0.38%-5.18%-139.96%
57
Neutral
€11.15B-6.00%0.01%
44
Neutral
C$980.54M-6.82-13.68%1.81%17.37%-32.98%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:ACT
AlzChem Group AG
156.60
109.76
234.33%
DE:EVK
Evonik
17.94
0.06
0.31%
DE:WCH
Wacker Chemie AG
70.30
-27.20
-27.90%
DE:1COV
Covestro
60.50
5.86
10.72%
DE:BNR
Brenntag AG
56.74
-6.03
-9.61%
DE:LXS
LANXESS
26.00
0.82
3.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025